Board of Directors
QUEBEC CITY, Oct. 19 /CNW/ - Medicago Inc. (TSX-V: MDG), a biotechnology
company focused on developing highly effective and affordable vaccines based on
proprietary manufacturing technologies and Virus-Like Particles (VLPs), today
announced the appointment of Mr. Pierre Marc Johnson, attorney, physician and
former Premier of Quebec, to its Board of Directors. Mr. Johnson replaces Mr.
Damien Levesque, who is leaving the Board of Medicago after serving for nine
years. Mr. Levesque will continue to assist Medicago as a Consultant.
"We are pleased to welcome Mr. Johnson to Medicago's Board," said Dr. Randal
Chase, Chairman of the Medicago Board of Directors. "As one of Quebec's
prominent leaders, Mr. Johnson brings a wealth of strategic insight and solid
experience working in governments and businesses. His knowledge of public
policy and regulatory processes as well as business activities will make of Mr.
Johnson a great asset to Medicago in the future development and
commercialization of its novel influenza vaccines."
"On behalf of the Board, I would like to thank Mr. Levesque for his great
dedication and loyal service to Medicago since the inception of the Company.
His guidance was of great assistance to the development of our business,"
concluded Dr. Chase.
Mr. Johnson is a lawyer, physician, former Premier of Quebec and former
professor of law at McGill University. He has been Of Counsel with the offices
of Heenan Blaikie LLP since 1996. He is recognized for his expertise in
international trade negotiations and international partnerships as well as
environmental and health law. From 1976 to 1987, he was a member of the Quebec
Legislature Assembly and in senior cabinet positions before becoming Premier in
1985. He was a founding Vice-Chair of the Prime Minister's National Round Table
on the Environment and the Economy of Canada, chaired its Foreign Policy
committee for seven years. He also served as a Special Advisor to the Secretary
General of the United Nations Conference on Environment and Development (UNCED)
and to the North American Commission on Environmental Cooperation. Mr. Johnson
was a director of several major corporations and currently sits on the boards
of ACE Aviation Holdings Corporation, Air Canada and Holcim Canada; he chairs
the foresight committee of the Veolia Institute for the Environment of Paris.
In 2006, he was appointed chair of the board of directors of the Quartier de la
Santé (Health district corporation), a Montreal-based organization created to
foster diagnostic and therapeutic innovation. Mr. Johnson holds an honorary
doctorate from the Université Claude Bernard Lyon I, France. He is Fellow of
the Royal Society of Canada, Grand Officier of the Ordre de la Pléiade and
Grand Officer of the Ordre National du Québec.
Concurrently with his appointment, Mr. Johnson was granted 37,500 options at an
exercise price of $0.60. Said options are governed by the stock options plan of
the Company and will vest in three yearly installments.
Medicago is committed to provide highly effective and affordable vaccines based
on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza,
using a transient expression system which produces recombinant vaccine antigens
in non-transgenic plants. This technology has potential to offer advantages of
speed and cost over competitive technologies. It could deliver a vaccine for
testing in about a month after the identification and reception of genetic
sequences from a pandemic strain. This production time frame has the potential
to allow vaccination of the population before the first wave of a pandemic
strikes and to supply large volumes of vaccine antigens to the world market.
Additional information about Medicago is available at www.medicago.com.
Forward Looking Statements
This press release contains forward-looking statements which reflect Medicago's
current expectations regarding future events. The forward-looking statements
involve risks and uncertainties. Actual results could differ materially from
those projected herein. Medicago disclaims any obligation to update these
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release
For further information: Medicago, Inc., Andy Sheldon, President and CEO, (418)
658-9393; Medicago Inc., Arianna Vanin, Director, Investor Relations, (514) 796-
CO: Medicago Inc.
NI: BTC 2575 WNEWS
-0- Oct/19/2009 12:30 GMT
Press spacebar to pause and continue. Press esc to stop.